Expression of seven stem-cell-associated markers in human airway biopsy specimens obtained via fiberoptic bronchoscopy

Journal of Experimental & Clinical Cancer Research

Biwen Mo¹  Ming Jiang¹  Jianghong Wei¹  Jiying Wang¹  Changming Wang¹  Jingyan Lu¹  Dangyu Li³  Jinrong Zeng¹  Xiaoyang Wang²  Huina Yu¹  Laodong Li¹ 

[1] Division of Respiratory Diseases, Guilin Medical University Hospital, Guilin, Guangxi, China;VitroVivo Biotechnology, LLC, Rockville, MD, USA;Division of Respiratory Diseases, Nan Xi Shan Hospital, Guilin Medical University Hospital, Guilin, Guangxi, China

关键词: Diagnostic marker;    Therapeutic target;    Lung cancer;    Stem-cell-associated marker;   

Others  :  825110
DOI  :  10.1186/1756-9966-32-28

 received in 2013-03-10, accepted in 2013-05-13,  发布年份 2013

【 摘 要 】

Background

Previous reports have suggested that malignant transformations originate from adult stem cells, and may thus express the stem-cell-associated markers. The purpose of this study is to investigate the differential expression and clinical significance of seven stem-cell-associated markers (Bmi1, CD133, CD44, Sox2, Nanog, OCT4 and Msi2) in lung cancer, providing new targets for the diagnosis and treatment of lung cancer.

Methods

In this study, we evaluated the differential expression of mRNA levels seven stem-cell-associated markers by semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) from 112 human lung cancer and 18 non-cancer tissues obtained by bronchoscopy. We further verified the differential expression of these markers by immunohistochemistry in 50 lung cancer specimens, 30 benign inflammatory lesion tissues and 20 non-tumor adjacent lung tissues.

Results

With the exception of OCT4, other markers Bmi1, CD133, CD44, Sox2, Nanog and Msi2 mRNA and protein were abundantly expressed in lung cancer. Additionally, Nanog expression was highly upregulated in lung cancer tissues and rarely presented in non-cancerous lung tissues, the sensitivity and specificity of Nanog mRNA reached 63.4% and 66.7%, respectively. Nanog therefore possessed high diagnostic value, however, CD44, Bmi1 and CD133 showed poor diagnostic value in lung cancer.

Conclusion

Nanog may serve as a promising diagnostic marker of lung cancer and potential therapeutic target in lung cancer.

【 授权许可】

   
2013 Li et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
• [2]Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
• [3]Reya T, Morrison SJ, Clarke MF, Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
• [4]Visvader JE, Lindeman GJ: Cancer stem cells in solid tumours:accumulating evidence and unresolved questions. Nat Rev Cancer 2008, 8:755-768.
• [5]Hassan KA, Chen G, Kalemkerian GP, Wicha MS, Beer DG: An embryonic stem cell-like signature identifies poorly differentiated lung adenocarcinoma but not squamous cell carcinoma. Clin Cancer Res 2009, 15:6386-6390.
• [6]Nguyen GH, Murph MM, Chang JY: Cancer stem cell radioresistance and enrichment: where frontline radiation therapy May fail in lung and esophageal cancers. Cancers 2011, 3:1232-1252.
• [7]Pine SR, Marshall B, Varticovski L: Lung cancer stem cells. Dis Markers 2008, 24:257-266.
• [8]Saeki M, Kobayashi D, Tsuji N, Kuribayashi K, Watanabe N: Diagnostic importance of overexpression of Bmi-1 mRNA in early breast cancers. Int J Oncol 2009, 35:511-515.
• [9]Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang CY, et al.: Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS One 2008, 3:e2637.
• [10]Moreira AL, Gonen M, Rekhtman N, Downey RJ: Progenitor stem cell marker expression by pulmonary carcinomas. Mod Pathol 2010, 23:889-895.
• [11]Leung EL, Fiscus RR, Tung JW, Tin VP, Cheng LC, Sihoe AD, et al.: Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS One 2010, 5:e14062.
• [12]Miyake H, Hara I, Gohji K, Yamanaka K, Arakawa S, Kamidono S: Urinary cytology and competitive reverse transcriptase-polymerase chain reaction analysis of a specific CD44 variant to detect and monitor bladder cancer. J Urol 1998, 160:2004-2008.
• [13]Müller FJ, Laurent LC, Kostka D, Ulitsky I, Williams R, Lu C, et al.: Regulatory networks define phenotypic classes of human stem cell lines. Nature 2008, 455:401-405.
• [14]Chapman CJ, Thorpe AJ, Murray A, Parsy-Kowalska CB, Allen J, Stafford KM, et al.: Immunobiomarkers in small cell lung cancer: potential early cancer signals. Clin Cancer Res 2011, 17:1474-1480.
• [15]Karoubi G, Cortes-Dericks L, Gugger M, Galetta D, Spaggiari L, Schmid RA: Atypical expression and distribution of embryonic stem cell marker, OCT4, in human lung adenocarcinoma. J Surg Oncol 2010, 102:689-698.
• [16]Nirasawa S, Kobayashi D, Tsuji N, Kuribayashi K, Watanabe N: Diagnostic relevance of overexpressed nanog gene in early lung cancers. Oncol Rep 2009, 22:587-591.
• [17]Sakakibara S, Nakamura Y, Satoh H, Okano H: Rna-binding protein Musashi2: developmentally regulated expression in neural precursor cells and subpopulations of neurons in mammalian CNS. J Neurosci 2001, 21:8091-8107.
• [18]Kharas MG, Lengner CJ, Al-Shahrour F, Bullinger L, Ball B, Zaidi S, et al.: Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med 2010, 16:903-908.
• [19]El-Bayoumi E, Silvestri GA: Bronchoscopy for the diagnosis and staging of lung cancer. Semin Respir Crit Care Med 2008, 29:261-270.
• [20]Ezeh UI, Turek PJ, Reijo RA, Clark AT: Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. Cancer 2005, 104:2255-2265.
• [21]Lin T, Ding YQ, Li JM: Overexpression of nanog protein is associated with poor prognosis in gastric adenocarcinoma. Med Oncol 2012, 29:878-885.
• [22]Meng HM, Zheng P, Wang XY, Liu C, Sui HM, Wu SJ, et al.: Overexpression of nanog predicts tumor progression and poor prognosis in colorectal cancer. Cancer Biol Ther 2010, 9:295-302.
• [23]Niu CS, Li DX, Liu YH, Fu XM, Tang SF, Li J: Expression of NANOG in human gliomas and its relationship with undifferentiated glioma cells. Oncol Rep 2011, 26:593-601.
• [24]Pan Y, Jiao J, Zhou C, Cheng Q, Hu Y, Chen H: Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade. Pathobiology 2010, 77:283-288.
• [25]Kikuchi J, Kinoshita I, Shimizu Y, Kikuchi E, Konishi J, Oizumi S, et al.: Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance. Cancer 2010, 116:3015-3024.
• [26]Woo T, Okudela K, Mitsui H, Yazawa T, Ogawa N, Tajiri M, et al.: Prognostic value of CD133 expression in stage I lung adenocarcinomas. Int J Clin Exp Pathol 2010, 4:32-42.
• [27]Sholl LM, Long KB, Hornick JL: Sox2 Expression in pulmonary non-small cell and neuroendocrine carcinomas. Appl Immunohistochem Mol Morphol 2010, 18:55-61.
• [28]Lu Y, Futtner C, Rock JR, Xu X, Whitworth W, Hogan BL, et al.: Evidence that SOX2 overexpression is oncogenic in the lung. PLoS One 2010, 5:e11022.
• [29]Chiou SH, Wang ML, Chou YT, Chen CJ, Hong CF, Hsieh WJ, et al.: Coexpression of oct4 and nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res 2010, 70:10433-10444.
• [30]Cantz T, Key G, Bleidissel M, Gentile L, Han DW, Brenne A, et al.: Absence of OCT4 expression in somatic tumor cell lines. Stem Cells 2008, 26:692-697.
• [31]Vrzalikova K, Skarda J, Ehrmann J, Murray PG, Fridman E, Kopolovic J, et al.: Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study. J Cancer Res Clin Oncol 2008, 134:1037-1042.